Hepatitis research and treatment最新文献

Assessment of Immunization to Hepatitis B Vaccine among Children under Five Years in Rural Areas of Taiz, Yemen. 也门塔伊兹农村地区五岁以下儿童乙型肝炎疫苗免疫评估

Hepatitis research and treatment Pub Date : 2017-01-01 Epub Date: 2017-03-06 DOI: 10.1155/2017/2131627

Fuad A A Alssamei, Najla A Al-Sonboli, Fawzi A Alkumaim, Nader S Alsayaad, Mohammed S Al-Ahdal, Tarig B Higazi, Atif A Elagib

{"title":"Assessment of Immunization to Hepatitis B Vaccine among Children under Five Years in Rural Areas of Taiz, Yemen.","authors":"Fuad A A Alssamei, Najla A Al-Sonboli, Fawzi A Alkumaim, Nader S Alsayaad, Mohammed S Al-Ahdal, Tarig B Higazi, Atif A Elagib","doi":"10.1155/2017/2131627","DOIUrl":"https://doi.org/10.1155/2017/2131627","url":null,"abstract":"Background. Hepatitis B virus (HBV) infection poses a major health problem worldwide. approximately 1 million deaths annually due to cirrhosis and hepatocellular carcinoma. Objectives. This study was conducted to determine the coverage rate of HBV vaccine and assess the vaccine protective response among children under five years old in rural areas of Yemen. Methods. A cross-sectional study was conducted from January to December 2015 in four districts of countryside Yemen. The target population was children aged from 6 to 59 months. 227 children were enrolled in the study. Questionnaire was used to collect of data. Serum samples were tested for anti-HBs antibodies by enzyme linked immunosorbent assay (ELISA). Anti-HBs level ≥ 10 IU/L was considered a protective response to the vaccine. Results. The coverage rate of HBV vaccine among children was 87.3%. A total of 143 (72.2%) children responded to the vaccine with anti-HBs level ≥ 10 IU/L, while 55 (27.8%) of the children had nonprotective anti-HBs levels of <10 IU/L (P = 0.003). Conclusion. This study revealed a good coverage rate of HBV vaccine in rural areas but the protective rate against HBV infection was moderate. A considerable proportion of vaccinated children should be considered for either revaccination or booster doses.","PeriodicalId":73232,"journal":{"name":"Hepatitis research and treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/2131627","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34877330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 16

Add-on Pegylated Interferon Alpha-2a Therapy in Chronic Hepatitis B Japanese Patients Treated with Entecavir. 恩替卡韦治疗慢性乙型肝炎日本患者的附加聚乙二醇化干扰素α -2a治疗

Hepatitis research and treatment Pub Date : 2017-01-01 Epub Date: 2017-04-11 DOI: 10.1155/2017/2093847

Hideyuki Tamai, Yoshiyuki Ida, Naoki Shingaki, Ryo Shimizu, Kazuhiro Fukatsu, Masahiro Itonaga, Takeichi Yoshida, Yoshimasa Maeda, Kosaku Moribata, Takao Maekita, Mikitaka Iguchi, Jun Kato, Masayuki Kitano

{"title":"Add-on Pegylated Interferon Alpha-2a Therapy in Chronic Hepatitis B Japanese Patients Treated with Entecavir.","authors":"Hideyuki Tamai, Yoshiyuki Ida, Naoki Shingaki, Ryo Shimizu, Kazuhiro Fukatsu, Masahiro Itonaga, Takeichi Yoshida, Yoshimasa Maeda, Kosaku Moribata, Takao Maekita, Mikitaka Iguchi, Jun Kato, Masayuki Kitano","doi":"10.1155/2017/2093847","DOIUrl":"https://doi.org/10.1155/2017/2093847","url":null,"abstract":"Entecavir requires long-term administration. Pegylated interferon (PEG-IFN) therapy leads to significant reduction of hepatitis B surface antigen (HBs Ag) levels. This study aimed to assess the safety and efficacy of adding PEG-IFN-α-2a to entecavir toward cessation of entecavir. A total of 23 patients treated with entecavir underwent add-on PEG-IFN-α-2a therapy (90 μg per week) for 48 weeks. Viral response (VR) was defined as more than 50% reduction of baseline hepatitis B surface antigen (HBs Ag) level at 72 weeks from the start of therapy. Complete response (CR) was defined as the decline of HBs Ag levels <100 IU/mL. Hepatitis B e antigen (HBe Ag) seroconversion rate was 25% (2/8), and VR rate was 52% (12/23). CR was observed in four patients (17%). However, CR rate in baseline HBs Ag level <2000 IU/mL and HBe Ag negative patients was 50% (4/8). Univariate analysis showed that the percentage of HBs Ag level reduction at week 12 was significantly associated with VR. The area under the curve value was 0.848. Adding PEG-IFN-α-2a to entecavir has limited efficacy. The percentage reduction of HBs Ag level at week 12 may be a useful predictor for VR.","PeriodicalId":73232,"journal":{"name":"Hepatitis research and treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/2093847","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34982392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Hepatitis B Vaccination Status among Health Care Workers in a Tertiary Hospital in Ethiopia. 埃塞俄比亚一家三级医院医护人员的乙肝疫苗接种情况。

Hepatitis research and treatment Pub Date : 2017-01-01 Epub Date: 2017-06-29 DOI: 10.1155/2017/6470658

Mohammed Biset Ayalew, Boressa Adugna Horsa

{"title":"Hepatitis B Vaccination Status among Health Care Workers in a Tertiary Hospital in Ethiopia.","authors":"Mohammed Biset Ayalew, Boressa Adugna Horsa","doi":"10.1155/2017/6470658","DOIUrl":"10.1155/2017/6470658","url":null,"abstract":"Background: Even though health professionals (HPs) need special consideration for hepatitis B virus (HBV) vaccination, this is not widely implemented in low- and middle-income countries. The aim of this study was to determine the vaccination status of health professionals against hepatitis B virus infection, to identify barriers to vaccination and to identify factors associated with vaccination status.Methods: This cross-sectional study was conducted from June 1 to 15, 2016. Data was collected using self-administered questionnaire and analysed using SPSS version 21. A test of association was done using binary logistic regression and P value less than 0.05 was considered statistically significant.Results: Out of 286 HPs included in the study 28.7% received full course vaccination against HBV. The most frequently mentioned reasons for not being vaccinated against HBV are unavailability of the vaccine (58.2%) and its cost (18.5%). Age, marital status, level of education, and type of profession have significant association with vaccination status.Conclusion: HBV coverage among HPs in Gondar University Hospital (GUH) is inadequate. This is mostly due to unavailability of the vaccine and its cost. Vaccination status significantly varies based on level of education, type of profession, age, and marital status. We recommend making vaccines available and accessible.","PeriodicalId":73232,"journal":{"name":"Hepatitis research and treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511672/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35205920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Viral Hepatitis Endemicity and Trends among an Asymptomatic Adult Population in Ho: A 5-Year Retrospective Study at the Ho Municipal Hospital, Ghana. 加纳何市医院5年回顾性研究:无症状成年人群中病毒性肝炎的流行趋势

Hepatitis research and treatment Pub Date : 2017-01-01 Epub Date: 2017-11-06 DOI: 10.1155/2017/6174743

Sylvester Yao Lokpo, James Osei-Yeboah, Gameli Kwame Norgbe, Patrick Kwasi Owiafe, Felix Ayroe, Francis Abeku Ussher, Mavis Popuelle Dakorah, John Gameli Deku, Nana Yaw Barimah Manaphraim, Emmanuel Akomanin Asiamah, Tibemponi Ntoni, Prince Senyo Kwasi Nyamadi, Edward Yiadom Boakye, Roseline Avorkliyah

{"title":"Viral Hepatitis Endemicity and Trends among an Asymptomatic Adult Population in Ho: A 5-Year Retrospective Study at the Ho Municipal Hospital, Ghana.","authors":"Sylvester Yao Lokpo, James Osei-Yeboah, Gameli Kwame Norgbe, Patrick Kwasi Owiafe, Felix Ayroe, Francis Abeku Ussher, Mavis Popuelle Dakorah, John Gameli Deku, Nana Yaw Barimah Manaphraim, Emmanuel Akomanin Asiamah, Tibemponi Ntoni, Prince Senyo Kwasi Nyamadi, Edward Yiadom Boakye, Roseline Avorkliyah","doi":"10.1155/2017/6174743","DOIUrl":"https://doi.org/10.1155/2017/6174743","url":null,"abstract":"Background: Using prospective blood donors as a proxy, this study was aimed at estimating the burden and five-year (2012-2016) trend of viral hepatitis (HBV and HCV) infection among asymptomatic adult population in Ho.Materials and methods: A retrospective analysis was done on secondary data extracted from the hospital archives comprising 4,180 prospective blood donors from January 2012 to December 2016. Demographic variables included age and sex, as well as place of residence. Screening results of serum infectious markers (HBV and HCV) were obtained.Results: The prevalence of asymptomatic viral hepatitis (HBV and HCV) infection in the general adult population was 6.94% and 1.84%, respectively. Females recorded a higher burden of HBV and HCV (8.3% and 5.0%) compared to their male peers (6.8% and 1.4%). A significant age variation in HBV antigenaemia was seen with HBV seropositivity peaking among the younger population (less than 20 years' group) at 11.24% and troughed among the older population (above 50 years' group) at 0.92%.Conclusion: Asymptomatic viral hepatitis among adult population in the Ho Municipality is estimated at the intermediate to high endemicity level. Preventive measures to reduce the burden are urgently needed and should be targeted at the younger generation.","PeriodicalId":73232,"journal":{"name":"Hepatitis research and treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/6174743","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35650509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

Prevalence of Hepatitis B Virus Infection among Pregnant Women Attending Antenatal Clinics in Vientiane, Laos, 2008-2014. 2008-2014年老挝万象产前门诊孕妇乙型肝炎病毒感染率

Hepatitis research and treatment Pub Date : 2017-01-01 Epub Date: 2017-03-29 DOI: 10.1155/2017/1284273

Marc Choisy, Sengdeuane Keomalaphet, Kinnaly Xaydalasouk, Fabrice Quet, Vatthanaphone Latthaphasavang, Yves Buisson

{"title":"Prevalence of Hepatitis B Virus Infection among Pregnant Women Attending Antenatal Clinics in Vientiane, Laos, 2008-2014.","authors":"Marc Choisy, Sengdeuane Keomalaphet, Kinnaly Xaydalasouk, Fabrice Quet, Vatthanaphone Latthaphasavang, Yves Buisson","doi":"10.1155/2017/1284273","DOIUrl":"https://doi.org/10.1155/2017/1284273","url":null,"abstract":"The Lao People's Democratic Republic (PDR) is still considered a highly endemic country for hepatitis B, mainly due to perinatal transmission of hepatitis B virus (HBV), despite efforts made since 2004 for universal immunization of newborns. The prevalence of HBV surface antigen (HBsAg) carriage in pregnant women is a relevant marker for the risk of mother-to-child HBV transmission. This study aimed to assess the changes in prevalence of HBV infection among pregnant women attending the Mahosot Prenatal Clinic (Vientiane Capital). Methods. A retrospective study was performed in the Mahosot Hospital Laboratory to collect and analyze all the results of HBsAg testing in pregnant women from 2008 to 2014. Results. Of a total of 13,238 tested women of mean age of 26 years, 720 women (5,44% [95 CI: 5.1-5.8%]) were found HBsAg positive, the annual prevalence ranging from 4.6% to 6.2%. A slight but steady and significant decrease in prevalence over the 7 years of the study could be documented. Conclusion. Although below the 8% hyperendemic threshold, the HBsAg prevalence observed in pregnant women in Vientiane reflects a high risk of HBV perinatal transmission and call for a widespread infant immunization with an HBV vaccine birth dose.","PeriodicalId":73232,"journal":{"name":"Hepatitis research and treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5390595/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34962302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 20

A Novel Structurally Stable Multiepitope Protein for Detection of HCV 一种结构稳定的新型HCV检测多表位蛋白

Hepatitis research and treatment Pub Date : 2016-01-28 DOI: 10.1155/2016/6592143

A. Galdino, J. Santos, Marilen Souza, Yanna Nóbrega, M. Xavier, M. Felipe, S. Freitas, F. Torres

{"title":"A Novel Structurally Stable Multiepitope Protein for Detection of HCV","authors":"A. Galdino, J. Santos, Marilen Souza, Yanna Nóbrega, M. Xavier, M. Felipe, S. Freitas, F. Torres","doi":"10.1155/2016/6592143","DOIUrl":"https://doi.org/10.1155/2016/6592143","url":null,"abstract":"Hepatitis C virus (HCV) has emerged as the major pathogen of liver diseases in recent years leading to worldwide blood-transmitted chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Accurate diagnosis for differentiation of hepatitis C from other viruses is thus of pivotal importance for proper treatment. In this work we developed a recombinant multiepitope protein (rMEHCV) for hepatitis C diagnostic purposes based on conserved and immunodominant epitopes from core, NS3, NS4A, NS4B, and NS5 regions of the virus polyprotein of genotypes 1a, 1b, and 3a, the most prevalent genotypes in South America (especially in Brazil). A synthetic gene was designed to encode eight epitopes in tandem separated by a flexible linker and bearing a his-tag at the C-terminal end. The recombinant protein was produced in Escherichia coli and purified in a single affinity chromatographic step with >95% purity. Purified rMEHCV was used to perform an ELISA which showed that the recombinant protein was recognized by IgG and IgM from human serum samples. The structural data obtained by circular dichroism (CD) spectroscopy showed that rMEHCV is a highly thermal stable protein at neutral and alkaline conditions. Together, these results show that rMEHCV should be considered an alternative antigen for hepatitis C diagnosis.","PeriodicalId":73232,"journal":{"name":"Hepatitis research and treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86869445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 12

Seroprevalence and Predictors of Hepatitis B Virus Infection among Pregnant Women Attending Routine Antenatal Care in Arba Minch Hospital, South Ethiopia 在南埃塞俄比亚Arba Minch医院接受常规产前护理的孕妇中乙型肝炎病毒感染的血清阳性率和预测因素

Hepatitis research and treatment Pub Date : 2016-01-24 DOI: 10.1155/2016/9290163

T. Yohanes, Z. Zerdo, Nega Chufamo

{"title":"Seroprevalence and Predictors of Hepatitis B Virus Infection among Pregnant Women Attending Routine Antenatal Care in Arba Minch Hospital, South Ethiopia","authors":"T. Yohanes, Z. Zerdo, Nega Chufamo","doi":"10.1155/2016/9290163","DOIUrl":"https://doi.org/10.1155/2016/9290163","url":null,"abstract":"Hepatitis B virus (HBV) is a serious cause of liver disease affecting millions of people throughout the world. When HBV is acquired during pregnancy, prenatal transmission can occur to the fetus. Therefore, this study is aimed at estimating seroprevalence and associated factors of HBV infection among pregnant women attending Antenatal Clinic (ANC) of Arba Minch Hospital, Southern Ethiopia. A facility based cross-sectional study was conducted on 232 pregnant women visiting ANC from February to April, 2015. Data regarding sociodemographic and associated factors were gathered using questionnaire. Serum samples were tested for hepatitis B surface antigen (HBsAg) by Enzyme Linked Immunosorbent Assay. Data was analyzed using SPSS version 20. The overall seroprevalence of HBV infection was 4.3% (95% CI: 2.2–6.9%). Multivariate analysis showed that history of abortion (AOR = 7.775; 95% CI: 1.538–39.301) and having multiple sexual partners (AOR = 7.189; 95% CI: 1.039–49.755) were independent predictors of HBsAg seropositivity. In conclusion, the prevalence of HBV infection is intermediate. Therefore, screening HBV infection should be routine part of ANC; health information on having single sexual partner for women of childbearing age and on following aseptic techniques during abortion should be provided to health facilities working on abortion.","PeriodicalId":73232,"journal":{"name":"Hepatitis research and treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85405563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 62

Atherosclerosis as Extrahepatic Manifestation of Chronic Infection with Hepatitis C Virus 动脉粥样硬化是慢性丙型肝炎病毒感染的肝外表现

Hepatitis research and treatment Pub Date : 2016-01-13 DOI: 10.1155/2016/7629318

T. Voulgaris, V. Sevastianos

{"title":"Atherosclerosis as Extrahepatic Manifestation of Chronic Infection with Hepatitis C Virus","authors":"T. Voulgaris, V. Sevastianos","doi":"10.1155/2016/7629318","DOIUrl":"https://doi.org/10.1155/2016/7629318","url":null,"abstract":"Chronic hepatitis C virus infection is associated with significant morbidity and mortality, as a result of progression towards advanced natural course stages including cirrhosis and hepatocellular carcinoma. On the other hand, the SVR following successful therapy is generally associated with resolution of liver disease in patients without cirrhosis. Patients with cirrhosis remain at risk of life-threatening complications despite the fact that hepatic fibrosis may regress and the risk of complications such as hepatic failure and portal hypertension is reduced. Furthermore, recent data suggest that the risk of HCC and all-cause mortality is significantly reduced, but not eliminated, in cirrhotic patients who clear HCV compared to untreated patients and nonsustained virological responders. Data derived from studies have demonstrated a strong link between HCV infection and the atherogenic process. Subsequently HCV seems to represent a strong, independent risk factor for coronary heart disease, carotid atherosclerosis, stroke, and, ultimately, CVD related mortality. The advent of new direct acting antiviral therapy has dramatically increased the sustained virological response rates of hepatitis C infection. In this scenario, the cardiovascular risk has emerged and represents a major concern after the eradication of the virus which may influence the life expectancy and the quality of patients' life.","PeriodicalId":73232,"journal":{"name":"Hepatitis research and treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87059279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 27

Combinations of siRNAs against La Autoantigen with NS5B or hVAP-A Have Additive Effect on Inhibition of HCV Replication. 针对 La 自身抗原、NS5B 或 hVAP-A 的 siRNA 组合对抑制 HCV 复制具有叠加效应。

Hepatitis research and treatment Pub Date : 2016-01-01 Epub Date: 2016-06-29 DOI: 10.1155/2016/9671031

Anirban Mandal, Krishna Kumar Ganta, Binay Chaubey

{"title":"Combinations of siRNAs against La Autoantigen with NS5B or hVAP-A Have Additive Effect on Inhibition of HCV Replication.","authors":"Anirban Mandal, Krishna Kumar Ganta, Binay Chaubey","doi":"10.1155/2016/9671031","DOIUrl":"10.1155/2016/9671031","url":null,"abstract":"Hepatitis C virus is major cause of chronic liver diseases such as chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Presently available direct-acting antiviral drugs have improved success rate; however, high cost limits their utilization, especially in developing countries like India. In the present study, we evaluated anti-HCV potential of several siRNAs targeted against the HCV RNA-dependent RNA polymerase NS5B and cellular factors, La autoantigen, PSMA7, and human VAMP-associated protein to intercept different steps of viral life cycle. The target genes were downregulated individually as well as in combinations and their impact on viral replication was evaluated. Individual downregulation of La autoantigen, PSMA7, hVAP-A, and NS5B resulted in inhibition of HCV replication by about 67.2%, 50.7%, 39%, and 52%, respectively. However, antiviral effect was more pronounced when multiple genes were downregulated simultaneously. Combinations of siRNAs against La autoantigen with NS5B or hVAP-A resulted in greater inhibition in HCV replication. Our findings indicate that siRNA is a potential therapeutic tool for inhibiting HCV replication and simultaneously targeting multiple viral steps with the combination of siRNAs is more effective than silencing a single target. ","PeriodicalId":73232,"journal":{"name":"Hepatitis research and treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4942654/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34693074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Two-Year Follow-Up Analysis of Telaprevir-Based Antiviral Triple Therapy for HCV Recurrence in Genotype 1 Infected Liver Graft Recipients as a First Step towards Modern HCV Therapy. 以替雷韦为基础的抗病毒三联疗法治疗基因1型感染肝移植受者HCV复发的两年随访分析，这是现代HCV治疗的第一步。

Hepatitis research and treatment Pub Date : 2016-01-01 Epub Date: 2016-04-18 DOI: 10.1155/2016/8325467

Fritz Klein, Ruth Neuhaus, Dennis Eurich, Jörg Hofmann, Sandra Bayraktar, Johann Pratschke, Marcus Bahra

{"title":"Two-Year Follow-Up Analysis of Telaprevir-Based Antiviral Triple Therapy for HCV Recurrence in Genotype 1 Infected Liver Graft Recipients as a First Step towards Modern HCV Therapy.","authors":"Fritz Klein, Ruth Neuhaus, Dennis Eurich, Jörg Hofmann, Sandra Bayraktar, Johann Pratschke, Marcus Bahra","doi":"10.1155/2016/8325467","DOIUrl":"https://doi.org/10.1155/2016/8325467","url":null,"abstract":"Objective. The introduction of protease inhibitors telaprevir and boceprevir in 2011 had extended the antiviral treatment options especially in genotype 1 infected hepatitis C relapsers and nonresponders to interferon/ribavirin therapy. The aim of this study was to analyze the long-term treatment efficiency of telaprevir-based triple therapy for patients with hepatitis C reinfection after orthotopic liver transplantation. Patients and Methods. We included 12 patients with histologically confirmed graft fibrosis due to hepatitis C reinfection. The treatment duration was scheduled as 12 weeks of telaprevir-based antiviral triple therapy followed by 36 weeks of dual therapy with pegylated interferon/ribavirin. The patients were followed up for two years after the end of triple therapy. Results. Of the 12 patients, 6 (50%) completed the full 48 weeks of antiviral treatment. An end of treatment response and a sustained virological response 52 weeks after the end of the antiviral treatment course were achieved in 8/12 (67%) and 7/12 (58%) patients, respectively. Conclusion. Telaprevir-based triple therapy was shown to be a long-term effective but complex treatment option for individual patients with hepatitis C graft. With the recent improvements in hepatitis C therapy options telaprevir may not be recommended as a standard therapy for this indication anymore. ","PeriodicalId":73232,"journal":{"name":"Hepatitis research and treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2016/8325467","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34394185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1